Right now, there is a debate occurring within the psychedelic community that is raising some interesting and important questions. From whom is it appropriate to take money to fund psychedelic research? How do we fund research, yet remain open and ethical?
The statement on open science and open praxis was published on Chacruna earlier this year, and was signed by many leaders in the psychedelic community. It aims for the following:
1) We will strive for intellectual and scientific integrity.
MAPS signed this statement. They have also recently been criticised for taking money from The Mercer Family Foundation to help fund its research.
COMPASS Pathways have also been criticised for their approach to funding research. COMPASS are now set to begin phase 2 clinical trials of psilocybin for depression. Compass is a for-profit company, and they have not signed the statement on open science and open praxis. Does this mean we should not be supporting this research?
Is it naive to think that psychedelic research can be performed without the backing of "big pharma"? The reality is, clinical trials are expensive and pharmaceutical companies can afford to pay for them. All they ask is that be able to make money in return. If we do not rely on pharmaceutical companies, how will expensive clinical trials get funded? Is this a compromise that need be taken to ensure these medicines make it to the general public quicker?
Melissa, vice-president of the APS, finished up a very successful time at Beyond Psychedelics in Prague last month. Melissa hosted a workshop on the intersection between mindfulness, psychedelics, flow states and creativity.
Melissa was also busy networking with other people in the international community. Watch Melissa talk with Dr Matthew Johnson about the relationship between psychedelic experience, mental health, society and the prominent role of the mystical experience in positive outcomes. Youtube video here.
Dr Dean Wright - The Blunt Report Podcast
Dr Dean Wright of the APS had a conversation with Konner Blunt on his Podcast, the Blunt Report.
In this episode of the podcast, Dean discusses some of the research surrounding psychedelics, showing that these drugs could be safer and far more effective than current mental health treatments. Not only that, we discuss some of the bumpy history of psychedelic medication and why the war on drugs might have created some unfounded misconceptions. Finally, Konner and Dean touched on what addiction is, how drugs should be viewed legally and reflected on the fact that mental health treatment could be very different today if research on psychedelics had not have been halted a few decades ago.